Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neuroendocrine Tumors × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Neoplasms 8 Carcinoma, Hepatocellular 8 Thyroid Neoplasms 5 Melanoma 5 Endometrial Neoplasms 5 Carcinoma, Renal Cell 5 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Cancer, Papillary 3 Colorectal Neoplasms 3 Adenocarcinoma, Follicular 3 Stomach Neoplasms 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma 2 Glioma 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Biliary Tract Neoplasms 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thyroid cancer, medullary 1 Thyroid cancer, Hurthle cell 1 Thyroid Diseases 1 Thyroid Carcinoma, Anaplastic 1 Solid Tumors 1 Sarcoma 1

Interventions

Everolimus 13 Octreotide 6 Magnetic Resonance Spectroscopy 5 lanreotide 4 Sunitinib 4 gallium Ga 68 dotatate 3 cabozantinib 3 arginyllysine 3 Specimen Handling 3 Nivolumab 3 Etoposide 3 Carboplatin 3 Bevacizumab 3 telotristat ethyl 2 surufatinib 2 pembrolizumab 2 pazopanib 2 pasireotide 2 lutetium Lu 177 dotatate 2 X-Rays 2 Temozolomide 2 Phantoms, Imaging 2 Oxaliplatin 2 Ipilimumab 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Cisplatin 2 Capecitabine 2 3-Iodobenzylguanidine 2 177Lu-DOTA-JR11 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02678780 2025-07-24

TALENT

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

123 enrolled 37 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡